Top 50 products in global drug sales in 2017: xiumeile won the "6 crown"

Source: in recent years, the top 50 sales volume of CPHI pharmaceutical online on February 26, 2018, Johnson & Johnson, Novartis, Roche and other pharmaceutical companies successively published 2017 financial statements, and Johnson & Johnson won the sales list with annual revenue of 76.5 billion US dollars; Sumeria continued to be strong, with sales volume increased by 2.69 billion US dollars in 2017, totaling 18.427 billion US dollars, rising to the "6-crown" Based on the financial report data published by each company, the author analyzes the top 50 products in global sales volume Behind the change of product pattern, the market development trend is implied The author analyzes the company and product characteristics from several aspects Top 50 products: domain analysis takes products as the starting point, and the author summarizes and ranks the sales of each drug respectively In top 50 products, there are 12 anti-tumor drugs, 9 autoimmune disease drugs, 8 diabetes drugs, 6 nervous system drugs, 5 antiviral drugs, and 10 other drugs (anticoagulant, respiratory system, vaccine, etc.) Top 50 products: the fall of hepatitis C products is more and more obvious in the impact of generic drugs Suofibuvir, imatinib and zeita have disappeared from the top 50 products in 2017, while keytruda, genvoya, epclusa and other products have entered the top 50 global sales volume for the first time There are several obvious eigenvalues to note: 1 Hepatitis C products began to shrink dramatically, such as Gilead's solvadi, harvoni and other hepatitis C products created a sales myth, and once escorted Gilead's market value to top 10 Gilead occupied the majority of the market share of hepatitis C market by virtue of hepatitis C drugs, reaching the peak sales in 2015, with a peak revenue of $19.14 billion From 2016, Geely's hepatitis C business began to shrink dramatically In 2017, solvadi fell out of the top 50, and harvoni fell from second to 16th For details, please refer to Geely's 2017 financial report: hepatitis C business continues to plummet and the new generation of AIDS products surged by 184% 2 The impact of generic drugs on 2017's top 50 is more and more obvious The sales of imatinib, rosuvastatin, Dieter insulin and other products are declining sharply Due to the listing of generic drugs, the market share of these products is shrinking rapidly 3 The market performance of irudinib, apixaban, keytruda and opdivo is outstanding In 2017, the sales of products represented by irudinib, apixaban, keytruda and opdivo increased significantly, especially the PD - (L) 1 antibody drugs represented by keytruda and opdivo At present, the market scale of PD - (L) 1 antibody drugs has exceeded $10 billion, and the market prospect is still very bright in 2018 Keytruda and opdivo will become the most shining star in the market of PD - (L) 1 antibody drugs 4 Several high sales share products Based on the statistics of the proportion of the sales of various products in the company's total revenue, the author finds that several drugs are the most promising The sales of these drugs are more than 30%, and some of them can even reach an amazing 88% High sales share has a certain impact on a company's long-term interests Once the product patent expires, the company will face a huge downward pressure We should pay attention to product upgrading and new business development
In the changing landscape of Top50, we can see that the competition of bio similar drugs / generic drugs is becoming increasingly fierce, and the iteration speed is very fast; the development of lenalidomide, Saban anticoagulant, CD4 / 6 inhibitor and Btk inhibitor is worthy of attention; the advantages of bio macromolecular drugs are constantly showing, and the development of bio similar drugs is becoming increasingly mature and standardized with the continuous maturity of engineering and technical means The price of EPO, long-acting insulin and other drugs will be reduced Technology is changing with each passing day Monoclonal antibody drugs and cell immunotherapy represented by Pd - (L) 1 are changing the world